{"text": "$rvmd a third rock, ras-targeting company!\n\nlead candidate, rmc-4630, is a shp2 inhibitor (in collaboration with $sny)\n\ncurrently in ph1 monotherapy, and ph1b/2 with cobmetinib (roche); plan to test with rtk, kras g12c ($amgn), and pd-1 inhibitors URL"}
